Notice: This company has been marked as potentially delisted and may not be actively trading. Bioblast Pharma (ORPN) News Today Add Compare Share Share Headlines Stock AnalysisCompetitorsHeadlinesTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Positive Outlook on BridgeBio Pharma’s BBP-812 Gene Therapy: Buy Rating ReaffirmedOctober 25, 2024 | markets.businessinsider.comPromising Outlook and Strategic Growth Support Buy Rating for Catalyst PharmaOctober 19, 2024 | markets.businessinsider.comPositive Developments and Potential Upside for BridgeBio Pharma: An Overweight Rating on Acoramidis Approval Prospects and Pipeline CatalystsOctober 18, 2024 | markets.businessinsider.com'Biopharma Crescent' sees rapid expansion fueled by recent investmentsOctober 12, 2024 | msn.comBuy Rating Affirmed on Urogen Pharma’s Promising Pipeline and Market Expansion PotentialOctober 4, 2024 | markets.businessinsider.comPharmaceutical giant partners with biotech company to produce animal-free protein for global nutrition: 'A win-win combination'September 27, 2024 | msn.comA weight loss drug developer's stock soars after a $198 million IPOSeptember 26, 2024 | msn.comA weight loss drug maker is aiming for a big IPOSeptember 25, 2024 | msn.comRoche Narrows Pharma Pipeline Amid Push Into Obesity MarketSeptember 24, 2024 | msn.comBioMarin Pharmaceutical: A Volatile But Growing TrajectorySeptember 17, 2024 | seekingalpha.comBridgeBio Pharma Stops Development Of BBP-631 For Congenital Adrenal HyperplasiaSeptember 11, 2024 | nasdaq.comBioMarin Pharmaceutical: Hold Rating Amidst Growth Potential and Competitive ChallengesSeptember 9, 2024 | markets.businessinsider.comBioMarin Pharmaceutical: A Buy Rating Based on Strong Growth and Operational Efficiency StrategySeptember 6, 2024 | markets.businessinsider.comBlast at Indian pharma factory kills 15 and injures 40, official saysAugust 23, 2024 | msn.comBridgeBio Pharma: Positioned for Growth with Acoramidis’ Market Potential and Positive Outlook amidst Stabilized ExpectationsAugust 22, 2024 | markets.businessinsider.comRobust Financials and Promising Clinical Trials Bolster Xenon Pharma’s Buy RatingAugust 9, 2024 | markets.businessinsider.comBalanced Outlook: BioMarin Pharmaceutical’s Strong Q2 Performance Amid Long-Term UncertaintiesAugust 7, 2024 | markets.businessinsider.comBarclays Keeps Their Buy Rating on BioMarin Pharmaceutical (BMRN)August 6, 2024 | markets.businessinsider.comBioMarin Pharma to Focus Roctavian Distribution in Push for ProfitabilityAugust 6, 2024 | marketwatch.comBuy Rating Affirmed for BridgeBio Pharma on Strong Program Prospects and Competitive EdgeMay 16, 2024 | markets.businessinsider.comResearchers discover new family of bacteria with high pharmaceutical potentialMay 16, 2024 | msn.comPromising Sales Growth and Strong Clinical Prospects Underpin Buy Rating for Urogen PharmaMay 13, 2024 | markets.businessinsider.comUmbrella Labs Elevates Biotechnological Frontiers with Launch of ALPHA MSH PEPTIDE 10MG VIALApril 23, 2024 | msn.comEssential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastomaApril 10, 2024 | markets.businessinsider.comAnaptysBio Inc.March 14, 2024 | barrons.comWhat's Going On With Rare/Orphan Disease Focused-Biodexa Pharmaceuticals Stock Friday?February 23, 2024 | msn.comLantern Pharma Inc Ordinary Shares LTRNFebruary 23, 2024 | morningstar.comQBiotics wins FDA orphan status for rainforest-derived cancer drugFebruary 18, 2024 | msn.comPBSV Pharma-Bio Serv, Inc.February 18, 2024 | seekingalpha.comAnaMar Announces US and EU Orphan Drug Designation for AM1476 for Treating Systemic SclerosisFebruary 5, 2024 | markets.businessinsider.comLumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical OfficerJanuary 4, 2024 | markets.businessinsider.comPlus Therapeutics Shares Jump Premarket on FDA Orphan DesignationNovember 3, 2023 | marketwatch.comChangzhou Qianhong Bio-Pharma Co. Ltd. AMarch 31, 2023 | wsj.com2023 Spinal Muscular Atrophy Medicine Market Report has the Potential to Deliver Genuine Review for DevelopmentMarch 1, 2023 | marketwatch.comSpinal Muscular Atrophy Medicine Market Size Global Research Report, 2023 - 2028February 18, 2023 | marketwatch.comSpinal Muscular Atrophy Medicine Market 2023 | Size, Growth Rate, Key Players Share, And Industry Trends Analysis with Global Forecast 2023-2028February 15, 2023 | marketwatch.comBioBlast Scant Data Links Drug to Improved Swallowing in PatientsFebruary 13, 2023 | thestreet.comBioMarin: Opportunity To Score Home Run With Latest Regulatory AdvancementsJanuary 30, 2023 | seekingalpha.comSpinal Muscular Atrophy Medicine Market 2023 : Research Report, Industry Growth, Competitors Analysis and Forecast 2028January 18, 2023 | marketwatch.comOrphan Drugs Market Size to Hit USD 340.84 Billion by 2027October 16, 2022 | finance.yahoo.comENLV Enlivex Therapeutics Ltd.September 21, 2022 | seekingalpha.comBioCryst Gets FDA Orphan Status for BCX9250 in Fibrodysplasia Ossificans ProgressivaAugust 31, 2022 | marketwatch.comBioCryst Secures FDA Orphan Drug Status For Rare Connective Tissue Disease CandidateAugust 31, 2022 | msn.comAro Biotherapeutics Receives FDA Orphan Drug Designation for ABX1100 for the Treatment of Pompe DiseaseAugust 12, 2022 | finance.yahoo.comBioCardia, Inc. (BCDA) CEO Peter Altman on Q2 2022 Results - Earnings Call TranscriptAugust 11, 2022 | seekingalpha.comBiosight Granted Orphan Drug Designation from the FDA for Aspacytarabine for the Treatment of Myelodysplastic SyndromesAugust 1, 2022 | finance.yahoo.comCitius Pharmaceuticals, Inc. Holds Pre-BLA Meeting with the FDA for I/ONTAK (denileukin diftitox) for the Treatment of Cutaneous T-Cell LymphomaJuly 12, 2022 | markets.businessinsider.comGlobal Orphan Drugs Global Market Report (2022 to 2031) - Featuring Amgen, Biogen, Novartis and Novo Nordisk Among Others - ResearchAndMarkets.comJuly 8, 2022 | apnews.comPyramid Biosciences Receives Orphan Drug Designation for PBI-200 From FDAJuly 7, 2022 | apnews.comAura Biosciences Gets Fast Track Designation for AU-011 Bladder Cancer TreatmentJune 30, 2022 | marketwatch.com Get Bioblast Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ORPN and its competitors with MarketBeat's FREE daily newsletter. Email Address Tim Sykes’ Urgent Trade Alert: “Make this move now” (Ad)WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT about Trump or Biden dropping out of the race… Click here to see a unique election-year trade ORPN Media Mentions By Week ORPN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ORPN News Sentiment▼0.000.86▲Average Medical News Sentiment ORPN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ORPN Articles This Week▼00▲ORPN Articles Average Week Get Bioblast Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ORPN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Galmed Pharmaceuticals News Today Sonnet BioTherapeutics News Today Oncternal Therapeutics News Today Panbela Therapeutics News Today Trevena News Today Altamira Therapeutics News Today TFF Pharmaceuticals News Today ASLAN Pharmaceuticals News Today PaxMedica News Today Evofem Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ORPN) was last updated on 12/4/2024 by MarketBeat.com Staff From Our PartnersElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredLock in this share price before 12/5When the team that built Zillow into a $16B real estate leader launches a new company, it’s worth paying atten...Pacaso | SponsoredCoins Set to Soar with a Pro-Crypto White HouseCoins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over...Crypto 101 Media | SponsoredAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredHas World War III already started?As global tensions are rising, so does the potential of direct conflict between the US and China. That's wh...Behind the Markets | SponsoredMeet the NYSE traded company behind a potentially blockbuster antiviral drugThis public company’s one lead drug alone, NV-387, potentially addresses a $2.5 to $4.3 billion market Imag...Smallcaps Daily | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioblast Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioblast Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORPN Stock Alerts